Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706711 | 1.00 | KDM4E (0.52) | KDM4ESMN1; SMN2ALDH1A1MAPTGPR35 | |
| SCHEMBL29446980 | 0.83 | SMN1; SMN2 (0.70) | KDM4ESMN1; SMN2ALDH1A1MAPTP2RX1 | |
| SCHEMBL837824 | 0.83 | SMN1; SMN2 (0.70) | KDM4ESMN1; SMN2ALDH1A1MAPTP2RX1 | |
| SCHEMBL18838552 | 0.83 | SMN1; SMN2 (0.70) | KDM4ESMN1; SMN2ALDH1A1MAPTP2RX1 | |
| SCHEMBL11198020 | 0.83 | ALDH1A1 (0.52) | KDM4ESMN1; SMN2ALDH1A1MAPTGPR35 | |
| SCHEMBL11198025 | 0.83 | ALDH1A1 (0.52) | KDM4ESMN1; SMN2ALDH1A1MAPTGPR35 | |
| SCHEMBL1510837 | 0.83 | NPSR1 (0.43) | KDM4ESMN1; SMN2ALDH1A1MAPTGPR35 | |
| SCHEMBL735333 | 0.82 | MMP2 (0.53) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL943656 | 0.82 | MMP2 (0.53) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL12006591 | 0.78 | ALDH1A1 (0.48) | KDM4ESMN1; SMN2ALDH1A1MAPTGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058900-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2004-03-25 | — | — | US | disclosed |
| US-20040043977-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2004-03-04 | — | — | US | disclosed |
| US-6683075-B1 | FUSED NITROGENHETEROCYCLIC AMIDES; ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667305-B1 | Alzheimer's disease; beta-amyloid peptide is a small fragment of the amyloid precursor protein | ATHENA NEUROSCIENCES, INC. | 2003-12-23 | — | — | US | disclosed |
| US-6653303-B1 | Fused nitroheterocycle with amino and amido functionality; inhibiting beta-amyloid peptide release and/or synthesis; Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6635632-B1 | Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6559141-B2 | Inhibit beta-amyloid peptide release and/or synthesis, use in treating Alzheimer's disease; for example, 5-(N'-(phenylacetyl)-L-alpha-(2-thienyl)glycinyl)-amino-7-methyl-5,7-dihydro-6H-dibenz(b, d)azepin-6-one | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
| US-6544978-B2 | Treating Alzheimer's disease both prophylactically and therapeutically | ATHENA NEUROSCIENCES, INC. | 2003-04-08 | — | — | US | disclosed |
| US-6506782-B1 | Compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta | ATHENA NEUROSCIENCES, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6495693-B2 | TREATMENT OF ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | AUDIA JAMES E (US) | 2001-09-06 | — | — | US | disclosed |
| US-6096782-A | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0942923-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022493-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043977-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | KDM4E 4628/4885SMN1; SMN2 2323/4885ALDH1A1 3990/4885 |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | APP, BACE1, IAPP | KDM4E 4391/4885SMN1; SMN2 1398/4885ALDH1A1 3198/4885 |
| US-20040058900-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | KDM4E 4628/4885SMN1; SMN2 2323/4885ALDH1A1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.